NCT02673398: Neratinib in Treating Older Patients With Metastatic HER2-Positive Breast Cancer

Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 60 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Adult)s under the age 60; Patients with untreated unstable brain metastasis – see trial for details

Comments are closed.

Up ↑